Ensign Peak Advisors’s Neumora Therapeutics NMRA Stock Holding History

Ensign Peak Advisors’s Portfolio NMRA Stock Details NMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.33M	Buy	+784,679	New	+$1.49M	﹤0.01%	806
2025 Q1	–	Sell	-150,000	Closed	-$1.59M	–	1710
2024 Q4	$1.59M	Hold	150,000	–	–	﹤0.01%	1055
2024 Q3	$1.98M	Hold	150,000	–	–	﹤0.01%	960
2024 Q2	$1.47M	Hold	150,000	–	–	﹤0.01%	1044
2024 Q1	$2.06M	Hold	150,000	–	–	﹤0.01%	913
2023 Q4	$2.56M	Hold	150,000	–	–	0.01%	816
2023 Q3	$2.12M	Buy	+150,000	New	+$1.87M	﹤0.01%	821

Other funds holding NMRA

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Ensign Peak Advisors's NMRA Position: Q2 2026 in Review

Ensign Peak Advisors opened a new position in Neumora Therapeutics (NMRA) in Q2 2026: 784,679 shares worth $1.33M. The stake represents ﹤0.01% of the portfolio and ranks #806 among its holdings. This is a return to the name: Ensign Peak Advisors previously reported a position in NMRA as recently as Q4 2024.

Ensign Peak Advisors first reported a position in NMRA in Q3 2023 and has held it in 7 quarters since. The position peaked at $2.56M in Q4 2023. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

Ensign Peak Advisors held 784,679 shares of Neumora Therapeutics worth $1.33M as of Q2 2026.
Neumora Therapeutics was a new Ensign Peak Advisors position in Q2 2026.
Neumora Therapeutics made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #806 holding.
Ensign Peak Advisors first reported a position in Neumora Therapeutics in Q3 2023 and has held it in 7 quarters since.
Ensign Peak Advisors's Neumora Therapeutics position peaked at $2.56M in Q4 2023.
113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.